- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis, Advanced Lung Disease
- Interventions
- Lumacaftor, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Antithymocyte globulin, Cyclosporine
- Drug
- Lead sponsor
- Neal Young, M.D.
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer
- Interventions
- gemcitabine, placebo, Erlotinib, apricoxib
- Drug
- Lead sponsor
- Tragara Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 39
- States / cities
- Tucson, Arizona • Bakersfield, California • Campbell, California + 36 more
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
- Interventions
- LI, Cyclophosphamide, Indomethacin, Zinc, Surgery, Cisplatin, Radiotherapy
- Biological · Drug · Dietary Supplement + 2 more
- Lead sponsor
- CEL-SCI Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 928 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 5
- States / cities
- Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Anaheim, California • Coronado, California • San Jose, California + 7 more
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- ENTO, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 9
- States / cities
- Miami, Florida • Atlanta, Georgia • Maywood, Illinois + 6 more
- Conditions
- Sleep
- Interventions
- Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 220 mg (BAYH6689), DPH 50mg, Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 16 Years to 45 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic HCV Infection
- Interventions
- LDV/SOF, RBV, GS-9669
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Decitabine and Cedazuridine (ASTX727), Venetoclax
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 20 more
- Conditions
- Pancreatic Cancer
- Interventions
- LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- PEN-866 Sodium, fluorouracil, Folinic acid, Niraparib
- Drug
- Lead sponsor
- Tarveda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 921 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 179
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more
- Conditions
- Bipolar Disorder, Cannabis-Related Disorder
- Interventions
- Quetiapine and placebo, Quetiapine and Topiramate
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Advanced GI Cancer
- Interventions
- MK-3475
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Leukemia
- Interventions
- CLAG Regimen, Gleevec®
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- Cetuximab, Imatinib
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
- Interventions
- Roginolisib, Obinutuzumab, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Simeprevir, Sofosbuvir
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 38
- States / cities
- Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel
- Drug
- Lead sponsor
- STCube, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- HIV Infections
- Interventions
- Truvada (tenofovir/emtricitabine), Kaletra (lopinavir/ritonavir)
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Gout
- Interventions
- RDEA594, Placebo, Allopurinol
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more